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Previous studies have documented an association between markers of sleep-disordered breathing (SDB) and metabolic syndrome.
However, it is not clear if there are gender or ethnic diﬀerences in this association. We examined 6,122 participants aged ≥20
years from the National Health and Nutrition Examination Survey 2005–08. Metabolic syndrome was deﬁned as the presence of
≥3 of the following components: (1) abdominal obesity, (2) elevated blood triglycerides, (3) low HDL cholesterol, (4) high BP,
and (5) hyperglycemia. SDB severity was deﬁned based on an additive summary score including sleep duration, snoring, snorting,
and daytime sleepiness. We found that short sleep duration, snoring, snorting, daytime sleepiness and the summary SDB score
were signiﬁcantly associated with metabolic syndrome independent of potential confounders. Compared to those without any
sleep disturbance, the multivariable odds ratio (OR) (95% conﬁdence interval [CI]) of metabolic syndrome among those with
three or more sleep disturbances was 3.92 (2.98–5.16). In subgroup analyses, this association was consistently present among men
and women and all race-ethnic groups. In summary, SDB was independently associated with metabolic syndrome in a nationally
representative sample of US adults.
1.Introduction
Sleep-disorderedbreathing(SDB)isacommonconditionaf-
fecting 1 in 5 adults in the USA and is associated with meta-
bolic abnormalities including diabetes [1, 2], hypertension
[3], and obesity [4]. Metabolic syndrome, a constellation of
metabolic abnormalities including obesity, high blood pres-
sure, dyslipidemia, and hyperglycemia is an established risk
factor for diabetes and cardiovascular disease [5]. Previous
studies have documented an association between a variety of
markers of SDB including snoring [6, 7], daytime sleepiness
[7], or sleep duration [8] and metabolic syndrome or its
components in the general population [9]. However, most of
the studies that examined the association between SDB and
metabolic syndrome assessed either a single marker of SDB
[6, 8, 9] or separate components of metabolic syndrome [9].
Studies have also documented gender [10, 11] or ethnic
diﬀerences [12, 13] in the prevalence of SDB. Men [10,
11] and African Americans [12, 13]w e r er e p o r t e dt oh a v e
increased prevalence of SDB in the US. Similar diﬀerences
in the prevalence of metabolic syndrome have been docu-
mented. In the National Health and Nutrition Examination
Survey (NHANES) 2003–2006, non-Hispanic black men and
womenwerereported to have higher prevalenceof metabolic
syndrome than non-Hispanic white men and women [14].
Further, the prevalence of components of metabolic syn-
drome including diabetes, hypertension and obesity is also
reported to be higher among African Americans [15].
Few previous studies have reported an association between
SDB and metabolic syndrome across gender or ethnic
groups using objectively deﬁned measures of SDB. In the
current study, we aimed to examine the association between2 Cardiology Research and Practice
subjective measures of SDB deﬁned by a combination of
snoring,snorting,daytimesleepinessandsleepduration,and
metabolic syndrome in a nationally representative sample
of US adults. In addition, we also examined the association
between subjective markers of SDB and metabolic syndrome
stratiﬁed by gender and ethnic groups.
2. Methods
The data for this study is derived from the National Health
and Nutrition Examination Survey 2005-06 and 2007-08.
Detailed description of NHANES study design and methods
areavailableelsewhere[16,17].Inbrief,theNHANESsurvey
included a stratiﬁed multistage probability sample repre-
sentative of the civilian noninstitutionalized US population.
Selection was based on counties, blocks, households, and
individuals within households and included oversampling
of non-Hispanic blacks and Mexican Americans in order
to provide stable estimates of these groups. We restricted
our study sample to participants aged greater than 20 years.
Questions on sleep were ﬁrst included in the NHANES in
2005-06. Of the 10,914 participants with information on
sleep variables, after excluding those with pregnancy (n =
393),prevalentcardiovasculardisease(n = 1,275),andthose
with missing information on plasma glucose, sleep variables
(n = 2,109),orvariablesincludedinthemultivariablemodel
(n = 1015), 6,122 were available for the ﬁnal analysis.
2.1. Assessment and Deﬁnition of Metabolic Syndrome Com-
ponents. Metabolic syndrome was deﬁned based on AHA-
NHLBI [18] revised deﬁnition of ATP-III guidelines as the
presence of 3 or more of the following components: (1)
abdominal obesity, waist circumference >102cm in men
and 88cm in women, (2) elevated blood triglycerides,
≥150mg/dL,(3)lowhigh-densitylipoprotein(HDL)choles-
terol, <40mg/dL in men and <50mg/dL in women, (4) high
blood pressure (BP), ≥130/85mmHg or use of BP medica-
tions, and (5) hyperglycemia deﬁned as a fasting serum glu-
cose ≥100mg/dL or on drug treatment for elevated glucose.
Waist circumference was measured to the nearest 0.1cm
at minimal respiration at the end of normal expiration with
a steel measuring tape placed at the high point of the iliac
crest when the participant was in a standing position. BP
was measured using a mercury sphygmomanometer, and an
average of three measurements was taken as the systolic and
diastolic BP value.
Fasting plasma glucose levels were measured using
hexokinase enzymatic method on Roche/Hitachi Modular P
Chemistry Analyzer at the Fairview Medical Center Labora-
tory at the University of Minnesota, Minneapolis Minnesota.
Serum total cholesterol, HDL cholesterol, and triglycerides
were measured enzymatically using the Roche Hitachi 717 in
2005, Roche Hitachi 717 and 912 in 2006, and Roche Mod-
ular P chemistry analyzer in 2007-2008. Detailed description
about the blood collection, processing and quality control
checks are provided in the Laboratory Procedures Manual
[19, 20].
2.2. Assessment of Exposure. A questionnaire on sleep habits
based on validated questions from previous epidemiolog-
ical studies was introduced in NHANES from 2005 till
2008 [21]. SDB was assessed from a set of questions on
sleep habits including “How much sleep do you usually get
at night on weekdays or workdays?,” “In the past 12 months,
how often did you snore while you were sleeping?,” “In the
past12months,howoftendidyousnort,gasporstopbreath-
ing while you were asleep?,” and “In the past month, how
oftendidyoufeelexcessivelyoroverlysleepyduringtheday?”
Based on the responses to the above questions, we created
four sleep variables: sleep duration, snoring, snorting, and
daytime sleepiness. Sleep duration coded in hours was cate-
gorized into ≤5, 6, 7, 8 and ≥9h. Snoring and snorting vari-
ableswerecategorizedinto0–2nights/week,3-4nights/week,
and 5 or more nights/week. Daytime sleepiness was catego-
rized into 0-1 time/month, 2–4 times/month, and 5 or more
times/month.
Since each of these sleep items were signiﬁcantly cor-
related (with Pearson correlation coeﬃcients ranging from
0.2 to 0.6; P<0.0001), we also created an SDB summary
score that indicates both the number of sleep items and
the severity. For the summary score, we ﬁrst dichotomized
the individual variables based on their clinical signiﬁcance
and previous literature. [12, 22, 23], A score of 1 was
assigned separately if the participants report sleep duration
of ≤5, snoring at least 3-4 nights/week, snorting at least 3-4
nights/week, and daytime sleepiness at least 5 times/month.
The summary score ranged from 0 to 4 corresponding to no
sleep disturbance to coexistence of all 4 sleep disturbances.
Diagnosed sleep apnea was assessed from two questions,
“Have you ever been told by a doctor or other health profes-
sional that you have a sleep disorder?” and among those who
answered aﬃrmatively, “What was the sleep disorder?” with
the response categorized into sleep apnea, insomnia, restless
legs, and others. Participants who reported sleep apnea were
classiﬁed to have diagnosed sleep apnea.
2.3. Assessment of Covariates. Information on age, gender,
race/ethnicity, smoking status, alcohol intake (g/day), level
of education, history of oral hypoglycemic intake or insulin
administration, and antihypertensive medication use was
obtained during a standardized questionnaire at home
interview. Educational attainment was categorized into less
than high school graduate, high school graduate, and more
than high school graduate. Individuals who had smoked
<100 cigarettes during their lifetime were considered never
smokers, those who had smoked ≥100 cigarettes lifetime
and currently not smoking were considered former smokers,
and those who had smoked ≥100 cigarettes lifetime and
currentlysmokingwereconsideredcurrentsmokers.Alcohol
consumption was categorized into never, former, current
moderate, and current heavy drinker based on questionnaire
response. Moderate physical activity was deﬁned as engaging
inmoderate-intensitysports,ﬁtness,orrecreationalactivities
that cause a small increase in breathing or heart rate such
as brisk walking, bicycling, swimming, or golf for at least
10 minutes continuously in a typical week. Depression wasCardiology Research and Practice 3
assessed using the Patient Health Questionnaire (PHQ-9),
a well-validated 9-item screening tool that asks questions
about the frequency of symptoms of depression over the past
2w e e k s[ 24]. Depression was deﬁned as a PHQ-9 score of 10
or higher, a validated cut-point commonly used in clinical
studies [24].
2.4. Statistical Analysis. We used analysis of covariance to
estimate mean levels of each component of metabolic syn-
drome across categories of summary sleep score. We exam-
ined the association between categories of individual sleep
variables, including snoring, snorting, daytime sleepiness
and sleep duration, and metabolic syndrome in two mul-
tivariable models. In the ﬁrst model, we adjusted for age
(years)andsex(female,male).Inthesecondmodel,weaddi-
tionally adjusted for race-ethnicity (non-Hispanic whites,
non-Hispanic blacks, Hispanic-Americans, others), educa-
tion (<high school, high school, >high school), smok-
ing (never, former, current), current alcohol consumption
(never,former,currentmoderateandcurrentheavydrinker),
and moderate physical activity (absent, present).
To examine the overall eﬀect of SDB markers on meta-
bolic syndrome, we created an additive summary SDB score
and examined the association between this summary SDB
score and metabolic syndrome in separate analyses. Tests
for trend were performed using the categories of individual
sleep variables and the summary score as an ordinal variable
in the corresponding multivariable models. To examine
the consistency of the association, we performed subgroup
analyses stratiﬁed by sex and race-ethnicity. Interactions
between SDB summary score and gender or race/ethnicity
wereassessedbyintroducingcross-productinteractionterms
in the corresponding multivariable models. All analyses
were weighted to account for the unequal probabilities of
selection, oversampling, and nonresponse using SUDAAN
(version 8.0; Research Triangle Institute, Research Triangle
Park, NC) and SAS (version 9.1.; SAS Institute, Cary, NC)
software. In a supplementary analysis, to assess the validity
of our self-reported sleep items and SDB summary score, we
examined the association between SDB summary score
and diagnosed sleep apnea in the multivariable model. In
a second analysis, we examined the association between
diagnosed sleep apnea and metabolic syndrome.
3. Results
The weighted prevalence of metabolic syndrome in the study
population was 37.3%. Table 1 shows the characteristics of
the study population. The mean age of the study population
was44.6yearsand50%ofthemwerewomen.Majorityofthe
participants were non-Hispanic whites (73.1%) and current
drinkers (75.1%). Fifty-nine percent were high school or
above educated and 23.6% were current smokers.
Table 2 shows the association between the various sleep
variables and metabolic syndrome. Compared to sleep
duration of 7h (referent), sleep duration ≤5hwaspositively
associated with metabolic syndrome in both the age, sex-
adjusted, and the multivariable models. Similarly, snoring
Table 1: Baseline characteristics of the study population.
Characteristics
Mean values ± standard error
(SE) or number (percentages)
(n = 6122)
Women (%) 2950 (50.1)
Age (years) 44.63 ± 0.46
Race/Ethnicity (%)
Non-Hispanic Whites 3047 (73.1)
Non-Hispanic Blacks 1214 (9.7)
Mexican Americans 1139 (7.9)
Others 722 (9.3)
Education categories (%)
Below high school 1622 (16.7)
High school 1481 (24.3)
Above high school 3019 (59.0)
Smoking (%)
Never smoker 3242 (52.6)
Former smoker 1461 (23.8)
Current smoker 1419 (23.6)
Alcohol intake, (%)
Never drinker 780 (10.1)
Former drinker 1104 (14.9)
Current moderate drinker 2529 (46.4)
Current heavy drinker 1709 (28.6)
Moderate physical activity (%) 2870 (53.9)
Total cholesterol (mg/dL) 0.38 ±0.01
Waist circumference (cm) 96.95 ± 0.42
Triglycerides (mg/dL) 157.98 ±2.5
HDL-cholesterol (mg/dL) 53.16 ± 0.34
Systolic blood pressure (mm Hg) 120.48 ±0.34
Diastolic blood pressure (mm Hg) 70.92 ± 0.29
Fasting glucose (mg/dL) 104.22 ±0.61
at least 3-4 nights/week, snorting at least 3-4 nights/week,
and daytime sleepiness at least 2–4 times/month were all
signiﬁcantly associated with metabolic syndrome in both
the age, sex-adjusted, and the multivariable models. Finally,
to examine the eﬀect of cooccurrence of sleep disturbances
on metabolic syndrome, we used the SDB summary score.
A signiﬁcant graded association was observed between
increasing SDB summary score and metabolic syndrome (P-
trend <0.0001).
Table 3 shows the association between the summary SDB
score and metabolic syndrome stratiﬁed by gender. Similar
to the main results in Table 2, a positive association was
observed between the summary SDB score and metabolic
syndrome in both men and women; however, the association
was stronger in women (P-interaction = 0.002). Table 4
shows the association between the summary SDB score and
metabolic syndrome stratiﬁed by race-ethnicity. Consistent
with the main results in Table 2, the association between4 Cardiology Research and Practice
Table 2: Association between sleep disordered breathing variables and metabolic syndrome.
Sleep variables Sample size
(Metabolic syndrome %)
Age, sex-adjusted
odds ratio (95% CI)
Multivariable adjusted∗
odds ratio (95% CI)
Sleep duration (hours)
≤5hrs 935 (40.3) 1.31 (1.04–1.64) 1.24 (0.98–1.57)
6hrs 1412 (38.8) 1.12 (0.94–1.34) 1.11 (0.93–1.34)
7hrs 1777 (36.6) 1 (referent) 1 (referent)
8hrs 1621 (35.7) 0.94 (0.78–1.14) 0.92 (0.76–1.11)
≥9hrs 377 (35.9) 1.01 (0.73–1.40) 0.97 (0.69–1.36)
P-trend 0.01 0.02
Snoring (nights/week)
0–2 2952 (27.2) 1 (referent) 1 (referent)
3-4 1188 (39.2) 1.67 (1.42–1.98) 1.69 (1.42–2.00)
≥5 1982 (51.7) 2.78 (2.38–3.25) 2.77 (2.38–3.24)
P-trend <0.0001 <0.0001
Snorting (nights/week)
0–2 5370 (35.0) 1 (referent) 1 (referent)
3-4 394 (47.7) 1.54 (1.16–2.06) 1.52 (1.16–1.98)
≥5 358 (60.2) 2.70 (2.21–3.30) 2.59 (2.13–3.14)
P-trend <0.0001 <0.0001
Daytime sleepiness (times/month)
0-1 3547 (36.1) 1 (referent) 1 (referent)
2–4 1583 (37.0) 1.15 (1.01–1.31) 1.15 (1.01–1.32)
≥5 992 (41.8) 1.54 (1.31–1.81) 1.44 (1.22–1.70)
P-trend <0.0001 <0.0001
Sleep summary score
0 2210 (26.9) 1 (referent) 1 (referent)
1 2424 (40.1) 1.80 (1.47–2.19) 1.80 (1.48–2.19)
2 1100 (46.7) 2.41 (2.03–2.87) 2.38 (1.99–2.85)
≥3 388 (56.8) 4.00 (3.05–5.24) 3.82 (2.89–5.04)
P-trend <0.0001 <0.0001
∗Adjusted for age (years), gender (male, female), race/ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education (below
high school, high school, above high school), smoking (never smoker, former smoker, current smoker), alcohol intake (never, former, current moderate,
current heavy), moderate physical activity (absent, present), and depression (absent, present).
summary SDB score and metabolic syndrome was found to
be consistently present in all race-ethnic groups (P-inter-
action = 0.6).
In a supplementary analysis, examining the association
between SDB summary score and diagnosed sleep apnea,
compared to those with SDB summary score of 0, the multi-
variable odds ratio (OR) (95% conﬁdence interval [CI]) of
sleep apnea among those with SDB summary score ≥3w a s
9.52 (5.73–15.80). In a second analysis, we examined the
association between diagnosed sleep apnea and metabolic
syndrome. 4.3% of the participants reported having diag-
nosed sleep apnea. Similar to the individual sleep variables,
a signiﬁcant positive association was observed between
diagnosed sleep apnea and metabolic syndrome. Compared
to those without diagnosed sleep apnea, the multivariable
odds ratio (OR) (95% conﬁdence interval [CI]) of metabolic
syndrome among those with diagnosed sleep apnea was 3.07
(1.88–5.00).
4. Discussion
In a representative sample of US adults, we found that mark-
ers of SDB including short sleep duration (≤5h), snoring at
least 3-4 nights/week, snorting at least 3-4 nights/week, and
daytime sleepiness at least 2–4 times/month were associated
with metabolic syndrome independent of age, sex, race-
ethnicity, education, smoking, alcohol consumption, and
physical activity. Further, an ad hoc summary SDB score that
provided a measure of the severity of SDB by counting the
cooccurrence of these four sleep disturbances showed that
compared to those without any SDB markers, those with
three or more SDB markers had nearly fourfold odds of
having metabolic syndrome. In subgroup analyses, the SDB-
metabolic syndrome association was found to be similar by
sex or race-ethnicity.
In the current study, we found that short sleep dura-
tion, snoring, and snorting were associated with metabolicCardiology Research and Practice 5










0 1011 (28.5) 1 (referent) 1 (referent)
1 1298 (38.4) 1.54 (1.17–2.02) 1.57 (1.19–2.07)
2 645 (46.0) 2.09 (1.63–2.68) 2.18 (1.69–2.82)
≥3 218 (50.3) 2.74 (1.98–3.79) 2.91 (2.12–4.01)
P-trend <0.0001 <0.0001
Women
0 1199 (25.7) 1 (referent) 1 (referent)
1 1126 (41.9) 2.03 (1.56–2.64) 2.01 (1.55–2.59)
2 455 (47.8) 2.72 (2.19–3.38) 2.52 (2.04–3.11)
≥3 170 (65.0) 6.14 (4.16–9.07) 5.28 (3.54–7.87)
P-trend <0.0001 <0.0001
∗Adjusted for age (years), race/ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education (below high school, high school,
above high school), smoking (never smoker, former smoker, current smoker), alcohol intake (never, former, current moderate, current heavy), moderate
physical activity (absent, present), and depression (absent, present).






odds ratio (95% CI)
Multivariable adjusted∗
odds ratio (95% CI)
Non-Hispanic Whites
0 1143 (28.9) 1 (referent) 1 (referent)
1 1179 (41.9) 1.76 (1.36–2.29) 1.76 (1.36–2.28)
2 536 (48.0) 2.31 (1.82–2.93) 2.25 (1.76–2.87)
≥3 189 (58.6) 4.08 (2.94–5.67) 3.71 (2.69–5.14)
P-trend <0.0001 <0.0001
Non-Hispanic Blacks
0 413 (21.2) 1 (referent) 1 (referent)
1 462 (33.5) 1.87 (1.35–2.59) 1.85 (1.33–2.58)
2 239 (39.6) 2.62 (1.60–4.29) 2.60 (1.60–4.23)




0 654 (21.3) 1 (referent) 1 (referent)
1 783 (36.1) 1.86 (1.26–2.75) 1.81 (1.22–2.69)
2 325 (45.7) 2.88 (1.96–4.23) 2.78 (1.87–4.14)
≥3 99 (59.2) 4.38 (4.49–7.70) 4.36 (2.45–7.75)
P-trend <0.0001 <0.0001
∗Adjusted for age (years), gender (male, female), education (below high school, high school, above high school), smoking (never smoker, former smoker,
current smoker), alcohol intake (never, former, current moderate, current heavy), moderate physical activity (absent, present), and depression (absent,
present).
syndromeconsistentwithpreviousstudies[7,8].Troxeletal.
has shown that snoring was associated with 3-year incidence
of metabolic syndrome in a community-based sample of US
adults[7].Leineweberetal.haveshownapositiveassociation
between snoring and metabolic syndrome in middle-aged
Swedishwomen[6].Halletal.reportedapositiveassociation
betweenbothshortandlongdurationofsleepandmetabolic
syndrome in a community-based sample of middle-aged
adults [8].
Few studies have examined the relation between SDB
and metabolic syndrome by gender or race/ethnicity using
objectivemeasuresofSDB.Sasanabeetal.inahospital-based6 Cardiology Research and Practice
case-control study in Japan observed a positive association
between SDB and metabolic syndrome in both men and
women; however, the association in women was short of
statistical signiﬁcance [25]. Nock et al. in a clinic-based
study in the US observed a positive association between
SDB and metabolic syndrome that was consistent across
gender and race-ethnic groups [26]. Nieto et al. reported a
positive association between SDB and metabolic syndrome
in a community-based sample comprising almost exclusively
white participants (96% whites) in the USA [27].
It is plausible that SDB may play a role in metabolic syn-
drome through several mechanisms. Intermittent hypoxia
and sleep fragmentation in SDB leads to insulin resistance
and metabolic alterations through activation of hypothal-
amo-pituitary-adrenal axis [28], excessive accumulation of
reactive oxygen species [29], enhanced production of proin-
ﬂammatory cytokines [30], and upregulation of leptin secre-
tion[31].StudieshavealsoshownthatSDBisassociatedwith
obesity, diabetes, hypertension, and lipid abnormalities [32].
The large multiethnic sample with rich information on
potential confounders and the rigorous methodology of
data collection in NHANES are the main strengths of the
study. Our study has some limitations. First, assessment of
SDB utilizing self-reported sleep items with no psychometric
support for their questionnaire items or any data to indicate
thatgroupingtheitemstogetherwaspsychometricallysound
might have introduced a bias. Second, we cannot exclude
the possibility of residual confounding due to measurement
error resulting from our less than comprehensive assessment
of physical activity. Third, our cross-sectional study design
limits making temporal associations between SDB and
metabolic syndrome.
Inconclusion,inanationallyrepresentativesampleofUS
adults, we found that markers of SDB, including short sleep
duration, snoring, snorting, and daytime sleepiness were
associated with metabolic syndrome independent of poten-
tial confounders. This association was consistently present in
men and women and across ethnic groups. If conﬁrmed by
future prospective studies, our ﬁndings may have important
clinical implications for screening and managing sleep
disorders in adults with metabolic syndrome.
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